



The complement cascade



- Platelet activation
- Inflammation
- Vascular permeability
- Clot formation
- Complement activation

Dobo J et al., Immunol Rev 2016

The complement cascade



Avacopan for the Treatment of ANCA-Associated Vasculitis

David R.W. Jayne, M.D., Peter A. Merkel, M.D., M.P.H., Thomas J. Schall, Ph.D., and Pirow Bekker, M.D., Ph.D., for the ADVOCATE Study Group*

C5a inhibitor

“...avacopan was noninferior but not superior to prednisone taper with respect to remission at week 26 and **was superior to prednisone taper with respect to sustained remission at week 52.**”

IMPROVED SURVIVAL FOLLOWING OMS721 TREATMENT OF HEMATOPOIETIC STEM CELL TRANSPLANT-ASSOCIATED THROMBOTIC MICROANGIOPATHY (HCT-TMA)


Alessandro Rambaldi, MD¹; Samer Khaled, MD²; Mark Smith, MBChB, FRACP, FRCPA³; Marco Zecca, MD⁴; Yok Lam Kwong, MD⁵; Kathleen Claes, MSc, MD, PhD⁶; Nelson Leung, MD⁷; Steve Whitaker, MD⁸

MASP-2 inhibitor




“Narsoplimab has been granted FDA Breakthrough Therapy designation in patients who have high-risk HSCT-TMA, as well as Orphan Drug designation for the prevention of complement-mediated TMAs and for the treatment of HSCT-TMA; and also for IgA nephropathy”

C1 esterase inhibitor (C1INH)


Licensed for replacement therapy in patients with C1INH deficiency (hereditary angioedema)



Ischemia/reperfusion injury



Reperfusion: spontaneous, angioplasty, thrombolysis



Reperfusion injury
 Tissue damage

30.06.2021

6

Yellon DM, NEJM. 2007